Roger von Moos
Roger von Moos
Head of medical Oncology Cantonal Hospital Graubuenden
Verified email at ksgr.ch - Homepage
TitleCited byYear
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer …
DH Henry, L Costa, F Goldwasser, V Hirsh, V Hungria, J Prausova, ...
J Clin Oncol 29 (9), 1125-1132, 2011
10122011
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ...
The lancet oncology 14 (1), 29-37, 2013
9032013
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
CJ Voskens, SM Goldinger, C Loquai, C Robert, KC Kaehler, C Berking, ...
PloS one 8 (1), e53745, 2013
3152013
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
G Fürstenberger, R Von Moos, R Lucas, B Thürlimann, HJ Senn, ...
British journal of cancer 94 (4), 524, 2006
2632006
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
F Strasser, TA Lutz, MT Maeder, B Thuerlimann, D Bueche, M Tschöp, ...
British journal of cancer 98 (2), 300, 2008
1692008
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
M Montemurro, P Schöffski, P Reichardt, H Gelderblom, J Schütte, ...
European journal of cancer 45 (13), 2293-2297, 2009
1632009
Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
R Dummer, R Panizzon, PH Bloch, G Burg
Dermatology 210 (1), 39-44, 2005
159*2005
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Y Waeckerle-Men, E Uetz-von Allmen, M Fopp, R von Moos, C Böhme, ...
Cancer Immunology, Immunotherapy 55 (12), 1524-1533, 2006
1312006
Pegylated liposomal doxorubicin-associated hand–foot syndrome: recommendations of an international panel of experts
R von Moos, BJK Thuerlimann, M Aapro, D Rayson, K Harrold, J Sehouli, ...
European journal of cancer 44 (6), 781-790, 2008
1292008
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical …
M Borner, D Koeberle, R Von Moos, P Saletti, D Rauch, V Hess, A Trojan, ...
Annals of oncology 19 (7), 1288-1292, 2008
1282008
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial …
T Ruhstaller, M Pless, D Dietrich, H Kranzbuehler, R von Moos, ...
Journal of clinical oncology 29 (6), 626-631, 2011
1192011
Pain outcomes in patients with advanced breast cancer and bone metastases: Results from a randomized, double‐blind study of denosumab and zoledronic acid
CS Cleeland, JJ Body, A Stopeck, R Von Moos, L Fallowfield, SD Mathias, ...
Cancer 119 (4), 832-838, 2013
1112013
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with …
D Henry, S Vadhan-Raj, V Hirsh, R Von Moos, V Hungria, L Costa, ...
Supportive Care in Cancer 22 (3), 679-687, 2014
1092014
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of …
D Arnold, T Andre, J Bennouna, J Sastre, PJ Osterlund, R Greil, ...
Journal of Clinical Oncology 30 (18_suppl), CRA3503-CRA3503, 2012
1082012
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
A Glaus, CH Boehme, B Thürlimann, T Ruhstaller, SF Hsu Schmitz, ...
Annals of oncology 17 (5), 801-806, 2006
1042006
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results …
X Pivot, A Schneeweiss, S Verma, C Thomssen, JL Passos-Coelho, ...
European journal of cancer 47 (16), 2387-2395, 2011
1022011
A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer …
D Henry
Eur J Cancer 7, 12, 2009
972009
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non …
D Koeberle, DC Betticher, R Von Moos, D Dietrich, P Brauchli, ...
Annals of oncology 26 (4), 709-714, 2015
912015
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
D Koeberle, R Burkhard, R Von Moos, R Winterhalder, V Hess, ...
British journal of cancer 98 (7), 1204, 2008
872008
Current concepts of treatment strategies in advanced or recurrent ovarian cancer
M Salzberg, B Thürlimann, H Bonnefois, D Fink, C Rochlitz, R von Moos, ...
Oncology 68 (4-6), 293-298, 2005
872005
The system can't perform the operation now. Try again later.
Articles 1–20